StockWatch
·
Q1 FY-2027 RESULTS · HINDUNILVR

HUL JQ26: 10% topline, best in 13 quarters; underlying PAT +9%, reported PAT dips 2% on base tax credit

PAT -3.2% YoY · revenue +10.1% · margins compressing · inline vs street

Q1 FY27 resultsHINDUNILVRHINDUSTAN UNILEVER LTD.28 Jul 2026 · 3 min read
Revenue

₹17,341 Cr

+10.1% YoY

PAT (consolidated)

₹2,680 Cr

-3.2% YoY

Net margin

15.29%

-1.3pp YoY

EPS

₹11.38

Hindustan Unilever's June quarter (JQ26/Q1 FY27) marks a clear topline inflection: consolidated turnover of ₹17,184 Cr grew ~10% YoY (revenue from operations ₹17,341 Cr, +10.1%), the company's highest growth in 13 quarters, and critically it was volume-and-price balanced — 5% underlying volume growth against 10% underlying sales growth, versus the sub-5% grind of recent quarters (3% in FH FY26, 5% in DQ25, 7% in MQ26, 10% now). Consolidated EBITDA rose 8% to ₹3,947 Cr, but EBITDA margin at 23.0% slipped ~40 bps YoY as palm-oil and other commodity inflation persisted; margin nonetheless held inside management's guided 22.5–23.5% band.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹17,341 Cr+6.1%+5%
Expenses₹13,822 Cr+6.9%+4%
PAT₹2,680 Cr-10.5%-3.2%
Net margin15.29%-2.7pp-1.3pp
EPS₹11.38-10.8%-3%

The profit optics need care. Reported consolidated PAT of ₹2,680 Cr fell ~2% YoY, but that decline is entirely a base effect — JQ25 carried a one-off tax credit. On a clean, before-exceptionals basis PAT actually grew ~9% to ₹2,731 Cr (from ₹2,498 Cr), broadly matching the revenue trajectory. So the honest read is +9% underlying, not −2%: steady-to-strong earnings, not a fall. The standalone print tells the same story — revenue from operations ₹16,657 Cr, PBT ₹3,548 Cr, reported PAT ₹2,631 Cr (−3% YoY reported, +9% before exceptionals). Standalone and consolidated do not diverge materially in direction.

2,049.532,126.692,203.852,281.012,358.172,092.104-2405-1806-1007-0307-2707-28Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹2,092.1, down 2.8% over the past month of trading.

₹ Cr
02,465.124,930.247,395.362,475Q4 FY25rev ₹15,670 Cr2,768Q1 FY26rev ₹16,514 Cr2,694Q2 FY26rev ₹16,241 Cr6,603Q3 FY26rev ₹16,441 Cr2,994Q4 FY26rev ₹16,351 Cr2,680Q1 FY27rev ₹17,341 Cr
Quarterly consolidated PAT, ₹ Crore

For context: revenue is at a 6-quarter high.

Beyond the headline

What the summary numbers don't show

Exceptional items net charge ₹75 Cr (restructuring ₹115 Cr, part-offset by ₹45 Cr asset-disposal gain); Boost crossed ₹1,000 Cr annual turnover

What management guided (4 FY-2026 call)
Management expects FY’27 to be better than FY’26, with competitive volume-led growth as the top priority. The mid-term EBITDA margin guidance is maintained in the range of 22.5% to 23.5%, though short-term cost inflation from geopolitical volatility will be navigated through calibrated pricing and savings. The strategi

This quarter: met

Against the Street this is roughly in line: brokerage previews (Business Standard) looked for ~10% PAT growth and 7–10% revenue on 5–7% volumes — HUL delivered revenue at the top of that range and ~9% underlying profit, with the reported-PAT dip a base-driven surprise rather than an operating miss. It also validates the last concall's guidance that FY27 would be better than FY26 with volume-led growth as the priority: all four segments grew (Home Care +14% USG, its best in three years; Beauty & Wellbeing +12%; Foods +7%; Personal Care +4%, pricing-led as palm-oil inflation bit volumes), and the guided EBITDA-margin range was defended. Concurrent developments — the new Unilever Fragrance Hub in Mumbai, AI-enabled distribution, and a Capital Markets Day set for 4 Sep 2026 — frame a premiumization/omni-channel investment cycle management flagged earlier. Management (CEO Priya Nair) framed it as its 'highest growth in thirteen quarters… driven equally by volume and price,' and the numbers support that claim on the top line; the caveat they own is continued short-term commodity and currency volatility.

  • W1

    Whether 5% UVG / 10% USG sustains into MQ27 — management wants volume-led growth as the top FY27 priority

  • W2

    EBITDA margin trajectory: 23.0% (−40 bps) with commodity/palm-oil inflation expected to persist short-term; guidance is 'around current guided range' 22.5–23.5%

  • W3

    Capital Markets Day (4 Sep 2026) for medium-term margin and portfolio-transformation guidance; Personal Care volume recovery as pricing normalises

Digital-native PDF, columns unambiguous. Current column = quarter ended 30-Jun-2026. Consolidated PAT ₹2,680 Cr includes NCI ₹7 Cr (owners ₹2,673 Cr); revenueFromOps = sale of products 16,172(std 15,599)+services+other op rev, matching segment total. Exceptional items net charge ₹75 Cr in JQ26 (restructuring ₹115 Cr less asset-disposal gains ₹45 Cr, etc.) vs ₹125 Cr in JQ25; JQ25 also had a one-off tax credit. Reported PAT −2% YoY but PAT-before-exceptionals +9% (₹2,731 Cr vs ₹2,498 Cr consol). Tax = current+deferred. Basis: consolidated primary.

Informational and educational content only. Not investment advice.